V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

AngioDynamics Executive Compensation (FY25)

ANGO · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): November 12, 2025
266 figures on this page: 256 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
James Clemmer, President and Chief Executive Officer, received $5,494,285 in total compensation for fiscal 2025, and compared with the $5,005,971 reported for fiscal 2024, Clemmer's total was 9.8% higher. For fiscal 2025, the company reported a chief executive pay ratio of 44:1, against median employee compensation of $124,242. Shareholders recorded 93.2% support for the say-on-pay proposal at the meeting held November 10, 2025 for fiscal 2025. Companies named in the disclosed peer group include Accuray Incorporated, Alphatec Holdings, Inc., Artivion, Inc., AtriCure, Inc. and Atrion Corporation, among others.
Chief executive, fiscal 2025
◇
James Clemmer
Latest say-on-pay support
=
November 10, 2025
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — James Clemmer: $5,005,971 → $5,494,285 (9.8% higher)
CEO pay ratio: 45:1 → 44:1 (2.2% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is AngioDynamics' chief executive and what were they paid?
James Clemmer, President and Chief Executive Officer, received $5,494,285 in total compensation for fiscal 2025. Compared with the $5,005,971 reported for fiscal 2024, Clemmer's total was 9.8% higher.
What was AngioDynamics' say-on-pay result?
Shareholders recorded 93.2% support for the say-on-pay proposal at the meeting held November 10, 2025 for fiscal 2025.
Which companies are in AngioDynamics' peer group?
Companies named in the disclosed peer group include Accuray Incorporated, Alphatec Holdings, Inc., Artivion, Inc., AtriCure, Inc. and Atrion Corporation, among others.
What is AngioDynamics' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 44:1, against median employee compensation of $124,242.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Clemmer
President and Chief Executive Officer
◇—◇◇◇—◇◇
Stephen Trowbridge
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Laura Piccinini
Senior Vice President and General Manager, Cardiovascular and International
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Clemmer
President and Chief Executive Officer
◇—◇◇◇—◇◇
Stephen Trowbridge
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Laura Piccinini
Senior Vice President and General Manager, Cardiovascular and International
◇—◇◇◇—◇◇
Warren Nighan
Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Clemmer
President and Chief Executive Officer
◇—◇◇◇—◇◇
Stephen Trowbridge
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Laura Piccinini
Senior Vice President and General Manager, Cardiovascular and International
◇—◇◇◇—◇◇
Lawrence Weiss
Senior Vice President, Chief Legal Officer and Corporate Secretary
◇—◇◇◇—◇◇
Warren Nighan
Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
James C. ClemmerRSU◇——◇——◇
James C. ClemmerPSU◇◇◇—◇—◇
James C. ClemmerPSU◇◇◇—◇—◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Warren NighanOption◇—◇7/20/32
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇7/19/33
Option◇—◇7/21/31
Option◇—◇7/17/34
RSU◇◇——
Laura PiccininiOption◇—◇7/19/23
RSU◇◇——
Option◇—◇7/19/23
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇7/20/22
Option◇—◇7/17/24
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇7/17/24
Stephen TrowbridgeOption◇—◇7/20/32
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇7/17/34
Option◇—◇7/19/33
RSU◇◇——
RSU◇◇——
Option◇—◇7/21/31
James ClemmerRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇7/19/34
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇7/19/24
RSU◇◇——
Option◇—◇7/19/33
Option◇—◇7/20/32
Option◇—◇7/17/34
RSU◇◇——
RSU◇◇——
Lawrence WeissRSU◇◇——
Option◇—◇12/2/24
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Howard W. Donnelly
Board chair
◇◇————◇
Wesley E. Johnson Jr
◇◇————◇
Wesley E. Johnson, Jr
◇◇————◇
Jan Stern Reed
◇◇————◇
Eileen O. Auen
◇◇————◇
Lorinda A. Burgess
◇◇————◇
Karen A. Licitra
◇◇————◇
Michael E. Tarnoff
◇◇————◇
James C. Clemmer served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.
Stock ownership guideline: 3x base cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Accuray Incorporated ARAY
  • Alphatec Holdings, Inc. ATEC
  • Artivion, Inc. AORT
  • AtriCure, Inc. ATRC
  • Atrion Corporation ATRI
  • AxoGen, Inc. AXGN
  • Cutera, Inc. CUTR
  • Glaukos Corporation GKOS
  • Inari Medical, Inc. NARI
  • LeMaitre Vascular, Inc. LMAT
  • Nevro Corp. NVRO
  • Orthofix Medical Inc. OFIX
  • STAAR Surgical Company STAA
  • Surmodics, Inc. SRDX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025November 10, 2025=◇◇◇
2024November 12, 2024=◇◇◇
2023November 14, 2023=◇◇◇
2022November 3, 2022=◇◇◇
2021November 3, 2021=◇◇◇
2020October 13, 2020=◇◇◇
2019October 15, 2019=◇◇◇
2018October 10, 2018=◇◇◇
2017October 17, 2017=◇◇◇
2016October 25, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when AngioDynamics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact AngioDynamics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where AngioDynamics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether AngioDynamics' disclosed peer group is defensible, who names AngioDynamics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
266 figures on this page: 256 cited to the filing that reported them, 10 calculated from figures it prints.
256 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001140361-25-041542
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001628280-25-042704
    CEO Pay Ratio · Director Compensation Table · Grants of Plan-Based Awards for Fiscal Year 2025 · Outstanding Equity Awards at Fiscal 2025 Year-End · and 1 more section
  3. 0001140361-24-047071
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001628280-24-041344
    Summary Compensation Table for Fiscal Year 2024
  5. 0001140361-23-053522
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001628280-23-033186
    Summary Compensation Table for Fiscal Year 2023
  7. 0000914121-22-004127
  8. 0000914121-21-007073
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0000914121-20-003700
  10. 0000914121-19-002764
  11. 0000914121-18-001946
  12. 0000914121-17-001483
  13. 0000914121-16-001612
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “AngioDynamics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/ANGO (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about AngioDynamics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers AngioDynamics discloses

The companies named in ANGO's own disclosed peer group.

Accuray IncorporatedArtivion, Inc.AtriCure, Inc.AxoGen, Inc.Glaukos CorporationLeMaitre Vascular, Inc.Orthofix Medical Inc.STAAR Surgical Company

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy